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Abstract
Background
Since screening programs identify only a small proportion of the population as eligible for an
intervention, genomic prediction of heritable risk factors could decrease the number needing
to be screened by removing individuals at low genetic risk. We therefore tested whether a
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polygenic risk score for heel quantitative ultrasound speed of sound (SOS)—a heritable risk
factor for osteoporotic fracture—can identify low-risk individuals who can safely be excluded
from a fracture risk screening program.
Methods and findings
A polygenic risk score for SOS was trained and selected in 2 separate subsets of UK Bio-
bank (comprising 341,449 and 5,335 individuals). The top-performing prediction model was
termed “gSOS”, and its utility in fracture risk screening was tested in 5 validation cohorts
using the National Osteoporosis Guideline Group clinical guidelines (N = 10,522 eligible par-
ticipants). All individuals were genome-wide genotyped and had measured fracture risk fac-
tors. Across the 5 cohorts, the average age ranged from 57 to 75 years, and 54% of studied
individuals were women. The main outcomes were the sensitivity and specificity to correctly
identify individuals requiring treatment with and without genetic prescreening. The reference
standard was a bone mineral density (BMD)–based Fracture Risk Assessment Tool (FRAX)
score. The secondary outcomes were the proportions of the screened population requiring
clinical-risk-factor-based FRAX (CRF-FRAX) screening and BMD-based FRAX (BMD-
FRAX) screening. gSOS was strongly correlated with measured SOS (r2 = 23.2%, 95% CI
22.7% to 23.7%). Without genetic prescreening, guideline recommendations achieved a
sensitivity and specificity for correct treatment assignment of 99.6% and 97.1%, respec-
tively, in the validation cohorts. However, 81% of the population required CRF-FRAX tests,
and 37% required BMD-FRAX tests to achieve this accuracy. Using gSOS in prescreening
and limiting further assessment to those with a low gSOS resulted in small changes to the
sensitivity and specificity (93.4% and 98.5%, respectively), but the proportions of individuals
requiring CRF-FRAX tests and BMD-FRAX tests were reduced by 37% and 41%, respec-
tively. Study limitations include a reliance on cohorts of predominantly European ethnicity
and use of a proxy of fracture risk.
Conclusions
Our results suggest that the use of a polygenic risk score in fracture risk screening could
decrease the number of individuals requiring screening tests, including BMD measurement,
while maintaining a high sensitivity and specificity to identify individuals who should be rec-
ommended an intervention.
Author summary
Why was this study done?
• Osteoporosis screening identifies only a small proportion of the screened population to
be eligible for intervention.
• The prediction of heritable risk factors using polygenic risk scores could decrease the
number of screened individuals by reassuring those with low genetic risk.
• We investigated whether the genetic prediction of heel quantitative ultrasound speed of
sound (SOS)—a heritable risk factor for osteoporotic fracture—could be incorporated
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What did the researchers do and find?
• Using UK Biobank, we developed a polygenic risk score (gSOS) consisting of 21,717
genetic variants that was strongly correlated with SOS (r2 = 23.2%).
• Using the National Osteoporosis Guideline Group clinical assessment guidelines in 5
validation cohorts, we estimate that reassuring individuals with a high gSOS, rather
than doing further assessments, could reduce the number of clinical-risk-factor-based
Fracture Risk Assessment Tool (FRAX) tests and bone-density-measurement-based
FRAX tests by 37% and 41%, respectively, while maintaining a high sensitivity and spec-
ificity to identify individuals who should be recommended an intervention.
What do these findings mean?
• We show that genetic pre-screening could reduce the number of screening tests needed
to identify individuals at risk of osteoporotic fractures.
• Therefore, the potential exists to improve the efficiency of osteoporosis screening pro-
grams without large losses in sensitivity or specificity to identify individuals who should
receive an intervention.
• Further translational studies are needed to test the clinical applications of this polygenic
risk score; however, our work shows how such scores could be tested in the clinic.
Introduction
Screening programs are generally designed to identify a proportion of the screened population
whose risk of a clinically relevant outcome is high enough to merit an intervention. However,
usually only a small proportion of individuals who undergo screening is found to be at high
risk, indicating that much of the screening expenditure is spent on individuals who will not
qualify for intervention.
Osteoporosis is a common and costly disease that results in an increased predisposition to
fractures [1]. Many guidelines [2–6] aimed at the prevention of osteoporosis-related fractures
incorporate the Fracture Risk Assessment Tool (FRAX) [7,8], a validated method to risk strat-
ify individuals for treatment by assessing their 10-year probability of major osteoporotic frac-
ture. Guidelines vary widely, but often recommend a staged process where individuals are first
assessed with a clinical-risk-factor-based FRAX (CRF-FRAX), and those at increased risk of
fracture are then additionally characterized with a more expensive bone mineral density
(BMD)–based FRAX (BMD-FRAX) score. Such approaches are usually recommended in the
setting of enhanced case-finding strategies, but recently, a large randomized controlled trial
(SCOOP) demonstrated the potential benefit of community-based fracture risk assessment in
reducing rates of hip fractures in elderly women [9]. This trial used a strategy based on the
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National Osteoporosis Guideline Group (NOGG) screening strategy [3], which implements
fracture risk stratification through the use of FRAX scores. In this trial, the entire screened
population underwent FRAX assessment using clinical risk factors, and almost half (49%) had
a sufficiently high probability of fracture to warrant further testing using a BMD-FRAX test.
Yet, only 14% of the screened population had a resultant probability of fracture high enough
to warrant intervention. This suggests that a method that improves screening efficiency and
decreases the number of persons undergoing risk stratification, particularly BMD-FRAX
assessments, would be a welcome addition to the screening strategy.
Skeletal measures that predict fracture risk are highly heritable (50%–85%) and include
BMD and quantitative ultrasound speed of sound (SOS) measurements, which are highly cor-
related [10–13]. Recently, large cohort resources have enabled the genomic prediction of such
heritable clinical risk factors from genotypes through polygenic risk scores [14–20], which cap-
ture information from many single nucleotide polymorphisms assayed from genome-wide
genotyping. These assays assess common genetic variation at millions of single nucleotide
polymorphisms and cost approximately $40 in a research context. However, the clinical utility
of such polygenic risk scores is unclear, widespread replication of polygenic risk scores is cur-
rently lacking, and it is unknown whether they can aid in screening programs. Defining their
clinical relevance may be particularly relevant in a British context, where the National Health
Service aims to sequence 5 million individuals within 5 years [21].
Very large cohorts are required to train polygenic risk scores, and current cohorts lack suffi-
cient sample size to generate useful BMD polygenic risk scores. However, since BMD is
strongly correlated with SOS [22] and SOS has been measured in 341,449 individuals in UK
Biobank, we developed a polygenic risk score for SOS termed “gSOS” (for “genetically pre-
dicted SOS”) that could be used to identify individuals unlikely to have low enough BMD to
warrant a clinical intervention. To improve screening efficiency, such individuals could be
removed from an osteoporosis screening program prior to measurement of BMD. We then
tested the generalizability and potential benefit of incorporating gSOS into the NOGG guide-
lines using 5 cohorts, comprising 10,522 eligible individuals. Last, we tested if gSOS could
decrease the number of people requiring more detailed assessments, such as BMD measure-
ment, while still identifying those who require interventions to decrease their risk of fracture.
Methods
Overall study design and cohorts
The purpose of this study was not to predict fractures. Rather, the purpose of this study was to
understand if genetic prescreening could reduce the number of screening tests needed to iden-
tify individuals at risk of osteoporotic fractures. This study included 3 phases (Fig 1). The first
2 phases were conducted in 2 distinct subsets of the UK Biobank study cohort, and the final
phase in a further subset of UK Biobank combined with 4 other cohorts. Characteristics of the
cohorts are shown in Table 1, with the cohorts described in detail in Table A in S1 Tables.
The first phase used least absolute shrinkage and selection operator (LASSO) regression
[23] to train a set of polygenic risk score models to predict SOS in the UK Biobank Training
Set (N = 341,449). In phase 2, the polygenic risk score model explaining the most variance in
measured SOS in the UK Biobank Model Selection Set (N = 5,335) was selected and named
gSOS. The ability of gSOS to explain variance in measured SOS was then tested in the UK Bio-
bank Test Set (N = 84,768). In phase 3, gSOS was tested for its performance in a screening
strategy, based on NOGG guideline thresholds of fracture risk, applied to a population of
10,522 individuals derived from 5 separate cohorts. Inclusion in the screening program
required these individuals to be�50 years with at least 1 risk factor and available measurement
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of femoral neck BMD. This population comprised a further distinct subset of the UK Biobank
Test Set (N = 2,445), as well as individuals from the Canadian Longitudinal Study on Aging
(CLSA) (N = 2,931), the Study of Osteoporotic Fractures (SOF) (N = 2,094), Mr OS US
(2,026), and Mr OS Sweden (N = 1,026). Together these 5 cohorts in phase 3 are referred to as
the validation cohorts. Next, to test the effect of gSOS on fracture screening by age, we strati-
fied the CLSA cohort by age, dividing the population into 3 age groups: 50–59 years, 60–69
years, and�70 years. The CLSA cohort was chosen for this age-stratified analysis, because it
was the largest validation cohort and had the widest age range. To assess the performance of
gSOS in ancestries other than White British, we tested it in individuals in the UK Biobank Test
Set who were eligible for screening and were of non–White British ancestry, as defined by
genotypes (see S1 Text for further details of definition of ancestry; Table B in S1 Tables shows
the demographic and risk factor characteristics of the sub-population).
This study adheres to the GRIPS statement (see S1 Checklist) and did not have a pre-speci-
fied analysis plan [24]. Specific ethics approval was not required for this study.
SOS and BMD measurement
We decided to use polygenic risk scores to predict SOS, rather than BMD, because polygenic
risk scores require a large number of individuals with proper phenotyping and genome-wide
genotyping. The largest dataset for SOS is approximately 10-fold larger than that for BMD
Fig 1. Overall study design. BMD, bone mineral density; CLSA, Canadian Longitudinal Study on Aging; GWAS, genome-wide association study;
NOGG, National Osteoporosis Guideline Group; PRS, polygenic risk score; QC, quality control; SOF, Study of Osteoporotic Fractures; SOS, speed of
sound; UKB, UK Biobank.
https://doi.org/10.1371/journal.pmed.1003152.g001
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[10,25]. SOS also predicts fracture, with similar performance characteristics compared to
BMD, and the 2 measures are correlated (r = 0.4–0.6) [22]. However, since femoral neck BMD
is required for FRAX calculations used in screening programs [26], we required that all indi-
viduals in the phase 3 analysis have femoral neck BMD measure available. Details of SOS and
BMD measurement are available in S1 Text. All analyses used SOS standardized to a mean of 0
and standard deviation of 1.
Development of machine learning model to predict SOS
Training, model selection, and test datasets. To develop and test gSOS, we followed best
practices in clinical prediction to ensure unbiased estimates of model performance by develop-
ing the models in datasets distinct from the datasets that were used to test model performance
[27]. Participants in the UK Biobank with White British ancestry (see S1 Text), measured SOS,
and genotyping information (N = 426,811) were randomly assigned to the UK Biobank Train-
ing Set (80% of participants), the UK Biobank Model Selection Set (1.25% of participants), or
the UK Biobank Test Set (18.75% of participants) (Fig 1; Table 1). Since BMD was measured
in only 4,741 individuals in all of UK Biobank [28], these individuals were assigned to the UK
Biobank Test Set to enable them to be used in phase 3 of the study.
Genome-wide association study (GWAS). Using methods from our previous GWAS of
estimated BMD in UK Biobank [25], but using a different sample size and SOS as the outcome,
we undertook a GWAS for SOS in the UK Biobank Training Set (N = 341,449 individuals with
Table 1. Participant characteristics by dataset.
Participant characteristics Model development cohorts gSOS-based screening test cohorts
UK Biobank
Training Set
UK Biobank Model
Selection Set
UK Biobank Test
Set
CLSA SOF Mr OS US Mr OS
Sweden
Sample size 341,449 5,335 4,741 6,704 3,426 4,657 1,880
Individuals eligible for screening, N
(%)
— — 2,445 (51.6) 2,931
(43.7)
2,094
(61.1)
2,026
(43.5)
1,026 (54.6)
Age, mean (SD) 56.8 (8.0) 56.6 (8.1) 55.8 (7.6) 62.6 (9.9) 71.5 (5.3) 74.0 (6.0) 75.4 (3.2)
Women, N (%) 186,569 (55.6) 2,863 (53.7) 2,489 (52.5) 3,396
(50.7)
3,426
(100)
0 (0) 0 (0)
Smoker, N (%) 27,181 (8.0) 397 (7.4) 966 (20.4) 581 (8.7) 270 (7.9) 145 (3.1) 178 (9.5)
Previous fracture, N (%) 34,917 (10.2) 386 (8.1) 1,032
(15.4)
1,210
(35.3)
1,084
(23.3)
637 (33.9)
Use of glucocorticoids, N (%) 3,330 (1.0) 51 (0.8) 79 (1.7) 258 (3.9) 363 (10.6) 98 (2.1) 34 (1.8)
Alcohol user, N (%) — — — 1,189
(17.7)
98 (2.9) 182 (3.9) 52 (2.8)
Fall within last 12 months, N (%) 69,057 (20.2) 1,052 (20.0) 1,500 (31.6) 699 (10.4) 1,021
(28.2)
984 (21.1) 298 (15.9)
Rheumatoid arthritis, N (%) 3,312 (1.0) 41 (0.8) 28 (0.6) 191 (2.9) 252 (7.0) 226 (4.9) 27 (1.4)
Secondary osteoporosis, N (%) 14,541 (4.3) 215 (4.0) 192 (4.1) 313 (4.7) — — —
Parental history of fracture, N (%) — — — 820 (12.2) 404 (14.4) 599 (16.8) 164 (8.7)
Baseline CRF-FRAX score for MOF,
mean (SD)
5.1 (3.1) 5.0 (3.1) 4.8 (2.7) 8.1 (6.8) 18.7 (9.5) 9.5 (4.7) 11.1 (6.3)
Baseline BMD-FRAX score for MOF,
mean (SD)
— — 4.9 (2.6) 7.5 (5.8) 17.1 (9.5) 8.1 (4.4) 13.1 (5.6)
gSOS, mean (SD) — −0.002 (1.00) 0.043 (0.98) −0.005
(1.00)
0 (0.99) −0.033
(0.98)
−0.708 (0.46)
BMD-FRAX, bone-mineral-density-based Fracture Risk Assessment Tool; CLSA, Canadian Longitudinal Study on Aging; CRF-FRAX, clinical-risk-factor-based
Fracture Risk Assessment Tool; MOF, major osteoporotic fracture; SOF, Study of Osteoporotic Fractures.
https://doi.org/10.1371/journal.pmed.1003152.t001
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White British ancestry). We tested the additive allelic effects of each of the 13.9 million SNPs
passing quality control, separately, on SOS using a linear mixed model to adjust for cryptic
relatedness and population stratification [29], as well as adjusting for age, sex, assessment cen-
ter, and genotyping array (S1 Text). Linkage-disequilibrium-independent associations where
obtained using PLINK by clumping SNPs in linkage equilibrium at a r2 > 0.05 and selecting a
single most significant SNP from within each clumped set. To reduce potential bias due to
population stratification, the UK Biobank Training, Model Selection, and Test Sets included
only White British participants, while all other cohorts included only people of general Euro-
pean ancestry (as defined in S1 Text). Further, as stated above, the performance of gSOS-based
screening was also tested in non–White British participants in UK Biobank.
Polygenic risk scores using LASSO. Using the UK Biobank Training Set, we fitted 6
LASSO models [23] to predict SOS using only SNPs with p-values smaller than a chosen set of
thresholds (Table C in S1 Tables). The UK Biobank Model Selection Set was then used to iden-
tify the p-value threshold and regularization parameter (λ) that resulted in the lowest root
mean square error for the prediction of SOS. This p-value threshold and regularization param-
eter were then taken forward for testing in the UK Biobank Test Set. Hence, we ensured that
the performance of only 1 final polygenic risk score was evaluated in the UK Biobank Test Set.
We refer to this final predictor as gSOS, in which SOS is predicted only from genotype.
Traditional polygenic risk scores. Traditional polygenic risk scores [15] were derived
from the GWAS for SOS performed in the UK Biobank Training Set, without the use of
LASSO, by including different sets of SNPs, selected by p-value threshold and linkage disequi-
librium clumping as described in S1 Text (Table C in S1 Tables).
Generation of FRAX scores
FRAX risk scores for major osteoporotic fracture (hip, clinical vertebra, proximal humerus, or
wrist) can be generated with or without BMD, referred to in this paper as BMD-FRAX and
CRF-FRAX, respectively [26]. Therefore CRF-FRAX and BMD-FRAX were calculated for all
participants in each validation cohort [26]. FRAX clinical risk factors were assessed at the base-
line visit for each cohort and included age, sex, body mass index (BMI), previous fracture,
smoking, glucocorticoid use, rheumatoid arthritis, and secondary causes of osteoporosis. Mea-
sures of more than 2 daily units of alcohol and parental history of hip fracture were not avail-
able in UK Biobank and were set to “no” for this cohort, as suggested by FRAX guidelines. Not
all secondary causes of osteoporosis were available for the SOF, Mr OS US, and Mr OS Sweden
cohorts, and these variables were also set to “no” for these cohorts, as recommended by FRAX.
Age was recorded at baseline visit. Sex was self-reported and verified by genotype. Individuals
with discordant sex between self-report and genotype were excluded. CRF-FRAX and
BMD-FRAX were calculated for all participants in each of the clinical cohorts, using country-
specific FRAX models [26].
Genomic screening in fracture risk screening
In the absence of an international consensus on fracture risk screening [2,4,5,30], we chose to
use the assessment and management clinical algorithm developed by NOGG [3], since a
screening program similar to the NOGG screening strategy is supported by randomized con-
trolled trial evidence [9]. The NOGG screening strategy uses 10-year absolute probability of
fracture as calculated by FRAX and suggests treatment or reassurance based on thresholds of
risk, which are age dependent and consider competing risks. The NOGG guidelines (Fig 2)
also aim to identify individuals at risk for fracture in a cost-efficient manner by reserving clini-
cal visits and more costly BMD testing for those at intermediate risk, i.e., where the FRAX
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score lies close to an intervention threshold. This intervention threshold is equivalent to the
age-specific FRAX 10-year probability in women with a prior fragility fracture, since nearly all
such women would be recommended an intervention [3]. Individuals without any risk factors
are excluded from the CRF-FRAX assessment. By applying CRF-FRAX, individuals can be rec-
ommended for either an intervention (high risk), a BMD-FRAX assessment (intermediate
risk), or reassurance and no further participation in the screening program (low risk). Those
having a BMD-FRAX assessment can then be recommended an intervention if their resulting
10-year probability of major osteoporotic fracture exceeds the age-specific threshold, or they
can be reassured (see Fig 2).
Despite the efficiencies gained by using this stepwise approach [31], false negatives can
occur when interventions are not recommended to individuals who have a low CRF-FRAX-
based probability and are discharged from subsequent screening, whereas if they had under-
gone BMD-FRAX, would have qualified for intervention. Likewise, false positives can arise
when an individual is recommended for an intervention based on the CRF-FRAX score but
would not have qualified for an intervention with BMD-FRAX.
To try to reduce the number of individuals undergoing testing, particularly more costly
BMD testing, who would subsequently not require intervention, we introduced a gSOS-based
screening step in the NOGG algorithm, where individuals were reassured if their gSOS was
above a threshold (Fig 3). This is because individuals with a high SOS are likely to have a high
BMD and are thus less likely to be recommended for an intervention. The trade-off of this
strategy is that it could result in reassurance of individuals who, if their BMD was measured,
would have been recommended an intervention. This would result in a decrease in sensitivity
to identify individuals requiring an intervention. To calculate the sensitivity and specificity of
the gSOS-modified NOGG algorithm, we used BMD-FRAX as a reference standard within the
NOGG screening strategy (Fig 4). According to NOGG guidelines, women�50 years with a
Fig 2. NOGG screening strategy. Both CRF-FRAX and BMD-FRAX generate a 10-year probability of major osteoporotic fracture, which is used to
designate risk of fracture. BMD-FRAX, bone-mineral-density-based Fracture Risk Assessment Tool; CRF-FRAX, clinical-risk-factor-based Fracture
Risk Assessment Tool; NOGG, National Osteoporosis Guideline Group.
https://doi.org/10.1371/journal.pmed.1003152.g002
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prior fragility fracture are recommended treatment without further FRAX testing. As a result,
these individuals were assigned an intervention recommendation when calculating the sensi-
tivity and specificity of correct treatment assignment (Fig 4).
Since resources are often expended to measure BMD-FRAX in individuals whose final
probability of fracture is too low to warrant intervention, we also estimated the number of
Fig 3. NOGG screening strategy with a gSOS screening step. Both CRF-based FRAX and BMD-based FRAX generate a 10-year probability of major
osteoporotic fracture, which is used to designate risk of fracture. gSOS is standardized to have a mean of 0 and standard deviation of 1. BMD-FRAX,
bone-mineral-density-based Fracture Risk Assessment Tool; CRF-FRAX, clinical-risk-factor-based Fracture Risk Assessment Tool; NOGG, National
Osteoporosis Guideline Group.
https://doi.org/10.1371/journal.pmed.1003152.g003
Fig 4. Calculation of sensitivity and specificity of correct treatment assignment. BMD-FRAX, bone-mineral-
density-based Fracture Risk Assessment Tool; NOGG, National Osteoporosis Guideline Group.
https://doi.org/10.1371/journal.pmed.1003152.g004
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CRF-FRAX and BMD-FRAX tests that were performed but led to the individual being reas-
sured without a recommended intervention.
We chose the sex-specific thresholds of gSOS that reduced CRF-FRAX and BMD-FRAX
testing but minimized the loss of sensitivity to identify individuals who would be recom-
mended for treatment. This threshold was chosen using data from the UK Biobank Test Set
(S4 Fig). The generalizability of the selected gSOS threshold was then tested in the remaining 4
validation cohorts (CLSA, SOF, Mr OS US, and Mr OS Sweden). The number of CRF-FRAX
and BMD-FRAX tests performed but not leading to an intervention were counted. These anal-
yses were conducted in each validation cohort, men and women separately, and in all groups
combined. We also tested individuals of non–White British ancestry in UK Biobank (N = 350),
i.e., the individuals who remain subsequent to filtering out the White British subset and who
have available measurements of femoral neck BMD. The characteristics are provided in
Table B in S1 Tables.
Results
Cohort characteristics
Table 1 describes the FRAX risk factors for all of the cohorts. There were few clinically relevant
differences in any of the osteoporosis-related risk factors in the UK Biobank Training, Model
Selection, and Test Sets, as expected, since these sets were generated randomly. As planned, all
individuals from UK Biobank with BMD measures were included in the UK Biobank Test Set,
to ensure availability of BMD-FRAX scores as the reference standard. There were few differ-
ences in demographics or clinical risk factors between individuals with and without BMD
measured. The validation cohorts (CLSA, SOF, Mr OS US, and Mr OS Sweden) provided a
range of characteristics, allowing for a better assessment of the generalizability of results
(Table 1).
GWAS
After quality control (see S1 Text), 13,958,249 SNPs were included in the GWAS. The GWAS
in the training set identified 1,404 independent (r2� 0.05) genome-wide significant loci at a p-
value threshold of<5 × 10−8. S1 Fig shows the Manhattan and QQ plots for this GWAS.
Variance explained in SOS in the UK Biobank Model Selection Set
The polygenic risk score models trained with LASSO explained at most 25.0% (95% CI 23.0%–
27.0%) of the variance in SOS in the UK Biobank Model Selection Set (Table C in S1 Tables).
S2 Fig provides detailed information on the optimal algorithm tuning parameters. None of the
traditional polygenic risk scores performed better than the polygenic risk score derived from
the LASSO regression. S3 Fig demonstrates that, as expected, the estimated effects of the acti-
vated SNPs from the LASSO algorithm were attenuated compared to the effects estimated
from the GWAS.
Variance explained in SOS in the UK Biobank Test Set
Age, sex, and BMI explained 4.0% (95% CI 3.7%–4.2%) of the variance in SOS. Adding all
available FRAX clinical risk factors increased the variance explained to 5.3% (95% CI 5.0%–
5.6%). The polygenic risk score from the UK Biobank Model Selection Set explaining the most
variance in measured SOS was designated as “gSOS” and was then tested for its correlation
with SOS in the UK Biobank Test Set. This model explained 23.2% (95% CI 22.7%–23.7%) of
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the variance in measured SOS and included 21,717 SNPs activated from a total of 345,111
SNPs that had p-values for association with SOS of�5 × 10−4 (Table C in S1 Tables; Fig 5).
Screening by NOGG guidelines in validation cohorts
The validation cohorts comprised 10,522 individuals eligible for fracture risk screening
(Table 1). Both the sensitivity and specificity of the NOGG screening strategy to identify indi-
viduals at high enough risk to merit an intervention, compared to the reference standard,
BMD-FRAX, were high (99.6% and 97.1%, respectively; Fig 6; Table D in S1 Tables). This high
sensitivity and specificity required CRF-FRAX tests to be undertaken in 81% of the population
eligible for screening, with BMD-FRAX tests subsequently recommended in 37% of the popu-
lation. In total, 74% of those requiring CRF-FRAX tests were classified for reassurance, i.e.,
without a recommendation for an intervention. As well, just over one-third of all individuals
who received a BMD-FRAX test were classified for reassurance without intervention (Fig 6;
Table D in S1 Tables).
Screening incorporating a gSOS-based screening step
Using the UK Biobank Test Set, we selected the threshold of gSOS that would minimize the
number of BMD tests done in persons who would ultimately be reassured rather than receiv-
ing an intervention, but also would minimize the number of false negatives (S3 Fig). Applying
this threshold separately in men and women, we found that a threshold of standardized gSOS
set to 0.5 and 0 for men and women, respectively, balanced these goals in the UK Biobank Test
Set, and subsequently individuals above these thresholds were excluded from further screening
in the validation cohorts, prior to receiving a CRF-FRAX or BMD-FRAX test (Fig 3). The util-
ity of this threshold was then tested in all validation cohorts.
Fig 5. Variance explained in SOS by clinical risk factors and gSOS in the UK Biobank Test Set. Available FRAX clinical risk
factors included age, sex, BMI, smoking, previous fracture, use of glucocorticoids, rheumatoid arthritis, and secondary osteoporosis.
BMI, body mass index; FRAX, Fracture Risk Assessment Tool; SOS, speed of sound.
https://doi.org/10.1371/journal.pmed.1003152.g005
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Fig 6 demonstrates that applying a gSOS screening step in the validation cohorts resulted in
a small decrease in sensitivity to identify eligible participants for therapy, to 93.4%, but that the
specificity increased slightly, to 98.5%. However, the proportion of screened individuals
requiring CRF-FRAX testing decreased from 81% to 51% (representing a relative decrease of
37%) compared to NOGG-based screening without a gSOS screening step. Additionally, the
proportion of screened individuals requiring BMD-FRAX testing decreased from 37% to 22%
(representing a relative decrease of 41%) (Fig 6; Table D in S1 Tables).
The proportion of CRF-FRAX and BMD-FRAX tests that resulted in an individual being
excluded from the screening program without a recommendation for an intervention also
decreased from 74% to 46% and from 34% to 20%, respectively (Fig 6; Table D in S1 Tables).
Cohort-specific results are shown in Tables E–I in S1 Tables.
The positive predictive value for correct treatment assignment in all validation cohorts was
91.8% without a gSOS screening step and increased to 95.4% with the gSOS screening step
(Table D in S1 Tables; cohort-level results and subgroup results are available in Tables D–P in
S1 Tables).
Women and men separately
The SOF cohort was composed of only women, while Mr OS US and Mr OS Sweden were
composed of only men, providing the opportunity to explore performance characteristics by
sex. Further, we divided the UK Biobank Test Set and CLSA into sex-specific datasets (Tables
J–M in S1 Tables). Amongst 4,859 women who were eligible for screening in the cohorts
(SOF, UK Biobank Test Set, and CLSA), the sensitivity and specificity for correct treatment
Fig 6. Performance characteristics of screening with and without a gSOS screening step. BMD-FRAX, bone-mineral-density-based Fracture Risk
Assessment Tool; CRF-FRAX, clinical-risk-factor-based Fracture Risk Assessment Tool.
https://doi.org/10.1371/journal.pmed.1003152.g006
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assignment were high (99.9% and 95%, respectively). Nevertheless, 58% of the population
required CRF-FRAX tests, and 43% required BMD-FRAX tests (Table N in S1 Tables).
When applying a gSOS screening step, the sensitivity decreased marginally, to 94.6%, and
the specificity increased marginally, to 98.2%. The proportion of the population requiring a
CRF-FRAX test reduced from 58% to 27% (representing a relative decrease of 55%), while the
proportion requiring a BMD-FRAX test reduced from 43% to 20% (representing a relative
decrease of 55%) (Table N in S1 Tables).
Amongst the 5,668 men eligible for screening, the sensitivity and specificity were 96.9% and
98.2%, respectively, using CRF-FRAX alone as the screening step. In order to achieve this per-
formance, 100% of men had a CRF-FRAX test, and 31% required a BMD-FRAX test. The yield
of high-risk individuals from these tests was low, such that 94% of men receiving a CRF-FRAX
test were reassured, and 29% of those receiving a BMD-FRAX test were reassured (Table O in
S1 Tables). Applying a gSOS screening step to these men reduced the sensitivity to 82% while
maintaining a similar specificity at 99%. However, the proportion of men requiring a
CRF-FRAX test reduced to 72% (representing a relative decrease of 28%), and the proportion
undergoing BMD-FRAX reduced to 23% (representing a relative decrease of 25%).
Stratification by age
We next tested the performance of gSOS in different age strata to understand if the screening
efficiency improved more for one age group than another. Using the largest cohort, with the
largest variation in age (CLSA, N = 6,704), we found that gSOS had the highest performance in
individuals aged�70 years. Specifically, the sensitivity and specificity to identify individuals
who require an intervention remained high, at 99.6% and 94.9%, respectively. The proportion
of screened individuals requiring CRF-FRAX testing decreased from 73% to 37% (representing
relative decrease of 49%) compared to the NOGG screening strategy without a gSOS screening
step. Additionally, the proportion of screened individuals requiring BMD-FRAX testing
decreased from 24% to 12% (representing a relative decrease of 50%) (Table F in S1 Tables). In
contrast, in individuals aged 50–59 years, sensitivity reduced to 86%, but specificity was 99.6%.
The percent of individuals requiring CRF-FRAX and BMD-FRAX testing reduced by 51% and
50%, respectively. This demonstrates that gSOS pre-screening improves the efficiency of
screening, but that the sensitivity to correctly identify individuals requiring therapy is maxi-
mized in older age groups.
Non–White British individuals
We then assessed the effect of a gSOS pre-screening in individuals from UK Biobank with
dual-energy X-ray absorptiometry BMD measures who were of non–White British ancestry
(Table B in S1 Tables). We found that the results were generally consistent with those in indi-
viduals of White British ancestry. Specifically, the proportion of screened individuals requiring
CRF-FRAX testing decreased from 94% to 48% (representing a relative decrease of 49%) com-
pared to NOGG-based screening without a gSOS screening step. Additionally, the proportion
of screened individuals requiring BMD-FRAX testing decreased from 39% to 17% (represent-
ing a relative decrease of 57%) (Table P in S1 Tables).
The proportion of CRF-FRAX and BMD-FRAX tests that resulted in an individual being
excluded from the screening program without a recommendation for an intervention also
decreased from 92% to 47% and from 38% to 16%, respectively (Table P in S1 Tables).
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Discussion
By building a polygenic risk score using 341,449 individuals and validating its utility in fracture
risk screening in 5 separate cohorts totaling 10,522 individuals, we determined that genomics-
enabled fracture risk screening could reduce the proportion of people who require BMD-
based testing by 41%, while maintaining a high overall sensitivity and specificity for correct
treatment assignment. While these findings are not meant to be prescriptive, they indicate the
possible utility of polygenic risk scores in screening programs that are dependent on heritable
risk factors.
Fracture risk assessment is expensive, with estimates of approximately US$50,000 per qual-
ity-adjusted life year gained [32], but is less expensive, or even cost-saving, using NOGG
assessment strategies [33,34], because NOGG decreases the number of individuals who require
CRF-FRAX and BMD-FRAX testing. Current guidelines suggest testing a large proportion of
the population [2,3,5], yet most screened individuals are not identified as having a clinically
actionable level of fracture risk [9,35]. This circumstance provides an opportunity for geneti-
cally derived measures of risk to increase cost-efficiencies in healthcare systems where invest-
ments have been made in genome-wide genotyping. Already at least 7 large healthcare systems
have invested in genome-wide genotyping of a large proportion of their population, among
whom electronic health record data are available [36,37]. Since the costs associated with
genome-wide genotyping have now dropped below those of several routine clinical tests, the
use of polygenic risk scores could be particularly helpful in these environments since a one-
time genotyping cost could be used to generate several polygenic risk scores. However, there is
a clear need to study the translation of such polygenic risk scores to clinical applications [38]—
and the work presented here provides one example of how such scores could be translated to
the clinic.
Previous attempts to predict osteoporosis from genomic data did not substantially increase
discrimination compared to standard clinical measures alone, likely because the GWAS that
underpinned these attempts was derived from 32,961 individuals and explained only 5.8% of
the variance in BMD [39,40]. The improvement in variance explained in this study was attrib-
utable to the increase in sample size afforded by UK Biobank and to the LASSO regression’s
ability learn SNP associations with SOS jointly, as opposed to summing over independently
measured effects on BMD. Other attempts to predict BMD have been based on several dozen
genome-wide significant SNPs [39], whereas our approach used machine learning to jointly
consider the effects of 642,127 SNPs (Table C in S1 Tables). LASSO regression has recently
been used to predict estimated BMD, but from a GWAS sample size that was one-third of that
used here, explaining only 17.2% of the BMD variance, and it was not used in a screening pro-
gram [14]. Our work has improved the genomic prediction of BMD and demonstrated its
potential clinical relevance.
We observed similar predictive performance across all LASSO models in the model selec-
tion step (Table C in S1 Tables); therefore, it remains possible that a more parsimonious
model containing fewer SNPs would perform as well. As a result, further exploration of these
LASSO models is warranted in a future technical study. However, should a more complex
model with more SNPs prove to be ideal, the hinderance to clinical translation should be mini-
mal, as the computational burden is limited to the training of the models, and is not in the pre-
diction of an individual’s genetic risk.
The sensitivity and specificity to correctly assign intervention was maximized in individuals
�70 years of age. This could be clinically relevant because this is the age range for which the
SCOOP trial demonstrated that a community-based screening program could be effective in
reducing hip fractures [9].
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We acknowledge that for many practicing physicians, such as those in the UK, who have
access to an automatically generated electronic-health-record-based CRF-FRAX test, the result
of interest would be the reduction in BMD-FRAX tests. However, we observed no appreciable
difference in the sensitivity and specificity to correctly identify individuals requiring therapy if
the gSOS screening step was placed prior to the CRF-FRAX test or immediately after the
CRF-FRAX test. Tables E–O in S1 Tables show the results for a reduction in BMD-FRAX tests
by cohort and sex.
Limitations
We have generated a polygenic risk score for SOS, rather than BMD, since there are insuffi-
cient data resources to generate such a score for BMD. Nevertheless, the correlation between
SOS and BMD has enabled the identification of individuals unlikely to have a BMD low
enough to warrant an intervention. Further refinement could improve the efficiencies pre-
sented here, including a polygenic risk score for BMD, when sample sizes are large enough to
enable this. While nearly all FRAX risk factors were available for study, alcohol intake and
parental history of fracture were not available from the UK Biobank cohorts. However, these
were available in the other validation cohorts. Secondary causes of osteoporosis were not uni-
formly available in SOF, Mr OS US, and Mr OS Sweden. Nevertheless, CLSA provided similar
results to other cohorts and had all required information. Like participants in most cohort
studies, the participants used in these studies are, on average, healthier than the general popu-
lation [41]. Thus, external validation in a truly population-based study may provide helpful
estimates of the real-world performance of genomics-enabled fracture risk screening. While
we have tested the utility of gSOS in individuals of non–White British ancestry, the sample size
available for study was relatively small, and thus results should be replicated in additional
cohorts of different ancestry, underlining the need for large-scale GWAS datasets in individu-
als of non-European ancestry [42]. We recognize that different approaches could be taken to
incorporate polygenic risk scores into fracture risk screening, but here we offer a simple
approach that could be readily implemented in a genotyped population with required FRAX
risk factors using the NOGG strategy [9].
Conclusions
In summary, we have developed and tested gSOS, a polygenic risk score for SOS, which when
introduced into a fracture risk screening program decreased the number of people requiring
CRF-FRAX and BMD-FRAX assessments, while still maintaining a high sensitivity and speci-
ficity to identify individuals in whom an intervention should be recommended. These findings
highlight the role that genetic prediction could play in screening programs that rely upon heri-
table risk factors.
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